Postpartum Deworming: Improving Breastfeeding and Optimizing Infant Growth

This study is ongoing, but not recruiting participants.
Information provided by (Responsible Party):
Dr. Theresa Gyorkos, McGill University Health Center Identifier:
First received: December 7, 2012
Last updated: March 29, 2016
Last verified: March 2016
Women of reproductive age are considered a high-risk group for worm infections by the World Health Organization. Maternal infection and anemia contribute to infant malnutrition by affecting milk quality and quantity, and duration of exclusive breastfeeding. To date, no study has investigated the health benefits of postpartum deworming to infants or mothers. A randomized controlled trial will be conducted in Peru to investigate the effectiveness of integrating deworming into routine postpartum care. The primary measure of effect will be infant weight gain between birth and six months of age. Other infant and maternal health indicators will also be ascertained.

Condition Intervention Phase
Intestinal Diseases, Parasitic
Drug: Albendazole
Drug: Placebo
Phase 4

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)
Primary Purpose: Prevention
Official Title: Postpartum Deworming: Improving Breastfeeding and Optimizing Infant Growth

Resource links provided by NLM:

Further study details as provided by McGill University Health Center:

Primary Outcome Measures:
  • Mean (± standard deviation) weight gain (kg) [ Time Frame: Change between birth and six months of age ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • Infant morbidity [ Time Frame: 1, 6, 12, 24 months following birth ] [ Designated as safety issue: No ]
  • Maternal hemoglobin levels and anemia [ Time Frame: 1, 6, 12, 24 months following birth ] [ Designated as safety issue: No ]
  • Breastfeeding practices [ Time Frame: 1, 6, 12, 24 months following birth ] [ Designated as safety issue: No ]
    The prevalence of current, exclusive, predominant and partial breastfeeding will be used to assess breastfeeding practices. In accordance with WHO criteria, infants will be considered as exclusively breastfed if they ingest only breast milk (excluding vitamins and medications); considered as predominantly breastfed if, in addition to breast milk, they also ingest water, juice, teas, vitamins or medications, and considered as partially breastfed if their primary nutrition source is other than breast milk.

  • Maternal energy levels [ Time Frame: 1, 6, 12, 24 months following birth ] [ Designated as safety issue: No ]
    Maternal energy levels will be measured using an adapted 5-item version of the Fatigue Assessment Scale (FAS) (Michielsen et al. 2004). This scale assesses symptoms of physical and cognitive fatigue.

  • Maternal STH infection [ Time Frame: 1 and 6 months following birth ] [ Designated as safety issue: No ]
  • Breast milk quality [ Time Frame: 1 and 6 months following birth ] [ Designated as safety issue: No ]
    Mean concentrations of key breast milk quality indicators (i.e. macronutrients, immunological factors, vitamins, and minerals) will be used to assess breast milk quality.

  • Breast milk quantity transferred from mother to infant [ Time Frame: 1 and 6 months following birth ] [ Designated as safety issue: No ]

Estimated Enrollment: 1010
Study Start Date: February 2014
Estimated Study Completion Date: September 2016
Primary Completion Date: February 2015 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Albendazole
single dose 400 mg tablet of albendazole
Drug: Albendazole
Placebo Comparator: Placebo
Placebo Manufactured by Hersil Laboratories in Lima, Peru
Drug: Placebo


Genders Eligible for Study:   Female
Accepts Healthy Volunteers:   Yes

Inclusion Criteria:

  • Deliver at Hospital Iquitos
  • Plan to reside in Iquitos or neighbouring area for the next 24 months
  • Able to communicate in Spanish

Exclusion Criteria:

  • Deliver multiples
  • Delivery a stillborn or an infant with a serious congenital medical condition
  • Transfered to another hospital prior to discharge
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01748929

Asociación Civil Selva Amazónica
Iquitos, Peru
Sponsors and Collaborators
McGill University Health Center
Principal Investigator: Theresa W Gyorkos, PhD McGill University Health Center
Principal Investigator: Martin Casapia, MD, MPH Asociación Civil Selva Amazónica
  More Information

Publications automatically indexed to this study by Identifier (NCT Number):
Responsible Party: Dr. Theresa Gyorkos, Principal Investigator, McGill University Health Center Identifier: NCT01748929     History of Changes
Other Study ID Numbers: 12-198-GEN 
Study First Received: December 7, 2012
Last Updated: March 29, 2016
Health Authority: Canada: Ethics Review Committee
Peru: Ethics Committee
Peru: Instituto Nacional de Salud

Additional relevant MeSH terms:
Intestinal Diseases
Intestinal Diseases, Parasitic
Parasitic Diseases
Digestive System Diseases
Gastrointestinal Diseases
Anti-Infective Agents
Anticestodal Agents
Antimitotic Agents
Antineoplastic Agents
Antiparasitic Agents
Antiplatyhelmintic Agents
Antiprotozoal Agents
Mitosis Modulators
Molecular Mechanisms of Pharmacological Action
Pharmacologic Actions
Therapeutic Uses
Tubulin Modulators processed this record on May 01, 2016